Drugs / Rina-S
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05579366 | Dec 2022 → Jul 2027 expected | breast adenocarcinoma, endometrial cancer, fallopian tube carcinoma, hormone receptor-positive breast cancer +5 | Genmab | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07539311 | May 2026 → Sep 2028 expected | digestive system cancer | Genmab | Recruiting | No outcome recorded |
| Phase 2 | NCT07288177 | Jan 2026 → Nov 2027 expected | non-small cell lung carcinoma | Genmab | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07564141 | Jul 2026 → Dec 2029 expected | ovarian cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07604766 | Jun 2026 → Sep 2027 expected | refractory malignant neoplasm | Genmab | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07225270 | Apr 2026 → Oct 2028 expected | ovarian cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT07166094 | Nov 2025 → Aug 2029 expected | endometrial cancer | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT06619236 | Feb 2025 → Feb 2027 expected | refractory malignant neoplasm | Genmab | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rina-S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288177 ↗ |
| Route | Intravenous | “Intravenous infusion of Rina-S” NCT05579366 ↗ |